Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

DON'T BUY

Earnings have been coming down. Model priced right now is $30.60 which is a drop from $35/36 over the last 4/5 months. Also broke a key level. Possibility of dropping to $17.40 which would be its bottom.

Wealthica Track your Stocks in your Watch List

WAIT

On all metrics, it looks cheap but the main concern he has is they've had a tendency to disappoint over the last couple of quarters. Wait until there is a turn in earnings.

BUY

Has some faith in this stock. Strong distribution.

DON'T BUY

Has a problem with the credibility of management. Making an interesting transition from a generic company to a distributor. Would like to see a little more maturity.

DON'T BUY

Too many moving parts in this company which makes it hard to evaluate.

WEAK BUY

A lot of the negative news is now priced into the stock. Looking for reaffirmation that the company is getting back on track over the next couple of quarters.

WEAK BUY

Worst behind it. Risky

TOP PICK

Trading at a relatively low multiple based on forecast revenues/earnings. Excellent products.

Wealthica Track your Stocks in your Watch List

PAST TOP PICK

(A top pick Mar 3/04. Down 4.4%.) Starting to develop a bottoming process. Extremely high risk. Fundamentals are still uncertain. Treat as a trade.

DON'T BUY

Looks cheap, but the headlines are a risk to this company. Not worth the risk.

DON'T BUY

Too much obsession with this company which has a problem with management credibility, product questions and financial questions. A lot better pharmaceuticals out there.

DON'T BUY

Their investigation revealed the company's numbers were not totally correct. On a real accounting basis, it would show they are not growing at all and had negative cash flow.

DON'T BUY

Not a great story. Have some good products/technology. Not a fan of management. Hard to figure out exactly what the company is worth. Could drop further.

DON'T BUY

Would like their accounting and corporate governance to be more transparent before considering.

WEAK BUY

Just recently bought some. Has a massive array of products. Speculative.

Showing 421 to 435 of 714 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)